Literature DB >> 12522652

Dobutamine stress echocardiography in the evaluation of young patients with Kawasaki disease.

M V Zilberman1, G Goya, S A Witt, B Glascock, T R Kimball.   

Abstract

There has been no consistent approach to the follow-up of Kawasaki disease patients for remote coronary perfusion abnormalities. Dobutamine stress echocardiography (DSE) has become a standard method for evaluation of perfusion abnormalities in adults with coronary artery disease. In addition, DSE has been used with success in some pediatric patients. The purposes of this study were to evaluate safety and accuracy of DSE in the follow-up of patients with Kawasaki disease, to evaluate whether DSE adds any additional value to the resting echocardiogram, and to determine the association of DSE results with American Heart Association (AHA) risk level categories. DSE was performed 1 month to 13 years after acute Kawasaki disease in 47 patients (range, 3.8-22.6 years; 33 males and 16 females). Patients were stratified according to AHA risk level categories (I-V). Ischemia was defined as a new or worsening regional wall motion abnormality or >1 mm ST segment depression on the electrocardiogram during DSE. In 45/47 patients, DSE was completed successfully (i.e., achievement of target heart rate or development of ischemia). No patients in risk levels lower than V (i.e., patients without coronary artery stenoses) had positive DSE, whereas 2/4 (50%) in the risk level V category had positive DSE, both of whom had coronary occlusion >50% confirmed by angiography. Of the 2 AHA risk level V patients with negative DSE, 1 had extensive collateralization and the other had coronary obstruction <50%. DSE is a safe and feasible method for the evaluation of children with Kawasaki disease. DSE provides a confirmatory benefit and may be a useful screening alternative to cardiac catheterization during follow-up. Patients in AHA risk levels I-IV are unlikely to have dobutamine-induced coronary perfusion abnormalities. Patients in the risk level V category may or may not have positive DSE depending on the degree of both coronary obstruction and collateralization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522652     DOI: 10.1007/s00246-002-0327-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  20 in total

1.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

Review 2.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

3.  Quantification of myocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography.

Authors:  O Muzik; S M Paridon; T P Singh; W R Morrow; F Dayanikli; M F Di Carli
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

4.  Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography.

Authors:  D S Segar; S E Brown; S G Sawada; T Ryan; H Feigenbaum
Journal:  J Am Coll Cardiol       Date:  1992-05       Impact factor: 24.094

5.  Evaluation of myocardial ischemia in Kawasaki disease by dobutamine stress signal-averaged ventricular late potentials.

Authors:  Y Genma; S Ogawa; J Zhang; M Yamamoto
Journal:  Cardiovasc Res       Date:  1997-12       Impact factor: 10.787

6.  Feasibility of exercise stress echocardiography for the follow-up of children with coronary involvement secondary to Kawasaki disease.

Authors:  E Pahl; R Sehgal; D Chrystof; W H Neches; C L Webb; C E Duffy; S T Shulman; F A Chaudhry
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

7.  Dobutamine stress echocardiography for assessing coronary artery disease after transplantation in children.

Authors:  R L Larsen; P M Applegate; D A Dyar; P A Ribeiro; S D Fritzsche; N F Mulla; G S Shirali; M A Kuhn; R E Chinnock; P M Shah
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

8.  Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients.

Authors:  H Mertes; S G Sawada; T Ryan; D S Segar; R Kovacs; J Foltz; H Feigenbaum
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

9.  Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  A S Dajani; K A Taubert; M Takahashi; F Z Bierman; M D Freed; P Ferrieri; M Gerber; S T Shulman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

10.  Dobutamine stress echocardiography for detection of coronary artery stenosis in children with Kawasaki disease.

Authors:  N Noto; M Ayusawa; K Karasawa; H Yamaguchi; N Sumitomo; T Okada; K Harada
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

View more
  3 in total

1.  Stress echocardiography: a useful tool for children with aortic stenosis.

Authors:  Ronak Naik; Allen Kunselman; Elizabeth Wackerle; Gerald Johnson; Stephen E Cyran; Devyani Chowdhury
Journal:  Pediatr Cardiol       Date:  2013-02-02       Impact factor: 1.655

2.  Semi-supine exercise stress echocardiography in children and adolescents: feasibility and safety.

Authors:  P Ciliberti; I McLeod; F Cairello; J P Kaski; M Fenton; A Giardini; J Marek
Journal:  Pediatr Cardiol       Date:  2014-11-20       Impact factor: 1.655

Review 3.  Medium-size-vessel vasculitis.

Authors:  Michael J Dillon; Despina Eleftheriou; Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2009-11-28       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.